Roche Re-Models Around Disease Areas, Pulls Together R&D And Commercial
This article was originally published in PharmAsia News
Roche is taking a dual approach in reorganizing its global R&D business by centering on key disease areas and consolidating its full operations, from R&D to marketing, along those lines
You may also be interested in...
Following its restructuring, Pfizer's in-house manufacturing capacity will support approximately $48 billion in sales
Pfizer's latest corporate restructuring represents a shift away from its recent alignment of research & development and commercialization operations
Amgen's growth strategy calls for heavy investment in research & development and targeted agreements to expand its pipeline, rather than large-scale acquisitions, CEO Kevin Sharer said